Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2

NAActive, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

MET-4

Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NuBiyota

OTHER

lead

University Health Network, Toronto

OTHER

NCT03838601 - Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 | Biotech Hunter | Biotech Hunter